Literature DB >> 30124412

Fluconazole-Resistant Candida parapsilosis Bloodstream Isolates with Y132F Mutation in ERG11 Gene, South Korea.

Yong Jun Choi, Yae-Jean Kim, Dongeun Yong, Jung-Hyun Byun, Taek Soo Kim, Yun Sil Chang, Min Ji Choi, Seung Ah Byeon, Eun Jeong Won, Soo Hyun Kim, Myung Geun Shin, Jong Hee Shin.   

Abstract

We recently observed the emergence of fluconazole-resistant Candida parapsilosis bloodstream isolates harboring a Y132F substitution in Erg11p in South Korea. These Y132F isolates had a higher propensity to cause clonal transmission than other fluconazole-resistant isolates and persisted within hospitals for several years, as revealed by microsatellite typing.

Entities:  

Keywords:  Candida parapsilosis; South Korea; antimicrobial resistance; candidemia; drug resistance; fluconazole; fungi; microsatellite marker

Mesh:

Substances:

Year:  2018        PMID: 30124412      PMCID: PMC6106402          DOI: 10.3201/eid2409.180625

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Candida parapsilosis is the second most common species isolated from patients with Candida bloodstream infections (BSIs) in Latin America and eastern Asia (,). Although uncommon, fluconazole-resistant C. parapsilosis isolates harboring the Y132F substitution in Erg11p (referred to as Y132F isolates) have been reported in Brazil, the United States, and Kuwait (–). The precise reason for the emergence of C. parapsilosis Y132F isolates has yet to be defined; it may be related to selective drug pressure, and the mutation at position 132 may be a hot spot for resistance mediated by ERG11, a gene encoding the azole target (). Alternatively, C. parapsilosis Y132F isolate emergence may be associated with exogenous clonal transmission (). We recently observed the emergence and nosocomial spread of Y132F isolates in South Korea. In this study, we report a greater increase in the clonal spread of C. parapsilosis Y132F BSI isolates than of non-Y132F fluconazole-resistant isolates within hospitals during the past several years. We assessed the first 47 C. parapsilosis BSI isolates that were fluconazole-resistant (MIC ≥8 mg/L) according to the Clinical and Laboratory Standards Institute (CLSI) species-specific clinical breakpoint (,). All 47 isolates were obtained from multicenter surveillance cultures from 8 university hospitals (A–H) during 2005–2016. For all fluconazole-resistant isolates, we examined genotypic relationships using microsatellite typing. We defined >2 isolates with identical genotypes according to microsatellite typing as clonal isolates. We sequenced the ERG11 gene and 3 transcription factor genes: TAC1, which can lead to the upregulation of CDR; MRR1, which can lead to the upregulation of MDR; and UPC2, which can lead to the upregulation of ERG11 (); we compared the results with those of 20 fluconazole-susceptible (MIC 0.5–2 mg/L) isolates. This study was approved by the Institutional Review Board of Chonnam National University Hospital (IRB CNUH-2014-290). Of the 47 C. parapsilosis fluconazole-resistant isolates, 30 (63.8%) had the Y132F substitution in Erg11p; however, none of the 20 fluconazole-susceptible isolates had the Y132F mutation in ERG11. Recently, 31%–57% of fluconazole-resistant C. parapsilosis isolates from different parts of the world were reported to be Y132F isolates, but the Y132F mutation was absent in all fluconazole-susceptible isolates (–). These data confirm that a Y132F substitution in Erg11p is the predominant fluconazole resistance mechanism for C. parapsilosis worldwide. Microsatellite typing revealed that 4 clonal Y132F isolates (M1–4) were persistently recovered in 2 hospitals (A and B) over a period of 3–7 years, and the proportion of clonal isolates was much higher in Y132F isolates (86.7%, 26/30) than in non-Y132F fluconazole-resistant isolates (11.8%, 2/17) (Table). In a previous microsatellite study from a US surveillance study by Grossman et al. (), no hospital specificity was detected among 13 non-Y132F fluconazole-resistant isolates; however, 2 notable clusters of isolates from 17 Y132F isolates were found over 8- or 18-month periods. The results obtained in our study and those of Grossman et al. indicate that Y132F isolates may have a higher propensity to cause clonal transmission and persist in particular hospitals than do non-Y132F fluconazole-resistant isolates. The Y132F substitution in Erg11p has also been detected in C. auris isolates from Pakistan (10/16 isolates), India (12/17 isolates), and Venezuela (5/5 isolates); these isolates are strongly associated with clonal transmission (). Further studies are needed to determine whether the Y132F mutation in Erg11p has a direct effect on clonal transmission of C. parapsilosis or C. auris isolates.
Table

Molecular characterization of 47 fluconazole-resistant isolates and 20 fluconazole-susceptible isolates of Candida parapsilosis, South Korea*

Microsatellite
genotypes†
Hospital
No. isolates
MICs, mg/L‡
Amino acid substitutions§Isolation year (no. patients)
FLC
VRC
Erg11p
Mrr1p
Tac1p
Upc2p
Fluconazole-resistant with Y132F in Erg11p, n = 30 isolates
M1A88–320.25–0.5Y132FK177N2006 (1), 2009 (1), 2010 (2), 2011 (2), 2012 (1), 2013 (1)
B316–320.5Y132FK177N2012 (2), 2013 (1)
M2A108–320.125–0.5Y132FK177N2012 (1), 2016 (9)
M3A38–160.25Y132FK177N, Q1053*2007 (1), 2011 (1), 2012 (1)
M4A28–>640.5–4Y132FK177N2013 (1), 2016 (1)
M5A1320.25Y132FK177N2012 (1)
M6A180.5Y132FK177N2013 (1)
M7A180.25Y132FK177N2016 (1)
M8
C
1
64
2

Y132F



2016 (1)
Other fluconazole-resistant, n = 17 isolates
M9D2>641G583R2007 (1), 2009 (1)
M10E1160.5R398IL877P2005 (1)
M11A180.252006 (1)
M12E180.25R398IL877P2011 (1)
M13F1160.06R398IL877P2011 (1)
M14E180.125R398IL877P2012 (1)
M15G180.125R398IL877P2012 (1)
M16G180.06R398IL877P2012 (1)
M17E180.125N900D2012 (1)
M18C180.125R398IP250SL877P2012 (1)
M19C180.25R398IS1081PL877P2012 (1)
M20D180.125R398ID394N2012 (1)
M21E1320.5R398IP295RL877P2015 (1)
M22E1160.125R398I2015 (1)
M23H1320.125K128NW872C2015 (1)
M24
E
1
16
0.25


G927D


2016 (1)
Fluconazole-susceptible controls
M3A110.03K177N, Q1053*2010 (1)
M25C20.50.03R398I2012 (2)
M26F20.50.03–0.06R208G2012 (1), 2013 (1)
M27A120.062010 (1)
M28A10.50.03K177N, Q1053*2011 (1)
M29A110.06L877P2011 (1)
M30A110.03R208G2012 (1)
M31A10.50.03R208G2012 (1)
M32E120.032012 (1)
M33G10.50.03R208G2012 (1)
M34G10.50.032012 (1)
M35A10.50.03R208G2013 (1)
M36A110.06R398ID394N2013 (1)
M37A10.50.03R398I2013 (1)
M38D10.50.06R398I2014 (1)
M39D10.50.06R208G2014 (1)
M40E10.50.03R208G2015 (1)
M41A110.03R398IL877P2015 (1)

*CLSI, Clinical and Laboratory Standards Institute; FLC, fluconazole; VRC, voriconazole.
†For microsatellite typing, each strain was characterized by a genotype resulting from combination of the sizes of the 4 markers (CP1, CP4, CP6, and B). See the Technical Appendix Figure for results of microsatellite genotyping presented as an UPGMA tree.
‡Antifungal MICs were determined by the CLSI M27–A3 broth microdilution method (). The fluconazole MICs of 30 Y132F isolates determined by Etest were ≥8 mg/L. All 67 isolates tested were susceptible to amphotericin B (MIC 0.25–1 mg/L) and micafungin (MIC 0.25–2 mg/L) according to the CLSI method.
§All were homozygote alleles except for 6 heterozygote alleles (Q1053,* G583R, P250S, P295R, W872C, and G927D) in Mrr1p.

*CLSI, Clinical and Laboratory Standards Institute; FLC, fluconazole; VRC, voriconazole.
†For microsatellite typing, each strain was characterized by a genotype resulting from combination of the sizes of the 4 markers (CP1, CP4, CP6, and B). See the Technical Appendix Figure for results of microsatellite genotyping presented as an UPGMA tree.
‡Antifungal MICs were determined by the CLSI M27–A3 broth microdilution method (). The fluconazole MICs of 30 Y132F isolates determined by Etest were ≥8 mg/L. All 67 isolates tested were susceptible to amphotericin B (MIC 0.25–1 mg/L) and micafungin (MIC 0.25–2 mg/L) according to the CLSI method.
§All were homozygote alleles except for 6 heterozygote alleles (Q1053,* G583R, P250S, P295R, W872C, and G927D) in Mrr1p. Two previous studies conducted in the United States detected the Erg11p Y132F substitution in combination with the Erg11p R398I substitution in almost all C. parapsilosis BSI isolates (,). In addition, no Y132F isolates detected in a US surveillance study contained an MRR1 polymorphism, according to MRR1 sequence analysis results (). However, a single Y132F substitution in Erg11p was found in all 30 fluconazole-resistant isolates from South Korea hospitals. The same K177N substitution in Mrr1p was found in all Y132F isolates except 1; none of the Y132F isolates showed missense mutations in Tac1p or Upc2p (Table). Taken together, these findings demonstrate low genetic diversity among Y132F isolates from the same country (the United States or South Korea). In our study, 76.7% (23/30) of patients with Y132F isolates had no antifungal exposure within 30 days before candidemia detection, and their clonal transmission was not detected by routine hospital surveillance, partly because more than half of the patient hospitalizations did not overlap. These findings indicate that clonal Y132F isolates may be dormant over long periods and can survive and persist outside their host on hospital environmental surfaces, which may be similar to the behavior of C. auris (). Although our study was limited by the relatively low number of isolates, our data suggest that C. parapsilosis Y132F isolates should be identified in clinical microbiology laboratories to prevent further clonal transmission of BSI caused by Y132F isolates.

Technical Appendix

Results of microsatellite typing presented as an UPGMA tree.
  8 in total

1.  Epidemiology of candidemia.

Authors:  P Sandven
Journal:  Rev Iberoam Micol       Date:  2000-09       Impact factor: 1.044

2.  Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998.

Authors:  M A Pfaller; R N Jones; G V Doern; H S Sader; S A Messer; A Houston; S Coffman; R J Hollis
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

3.  Simultaneous Emergence of Multidrug-Resistant Candida auris on 3 Continents Confirmed by Whole-Genome Sequencing and Epidemiological Analyses.

Authors:  Shawn R Lockhart; Kizee A Etienne; Snigdha Vallabhaneni; Joveria Farooqi; Anuradha Chowdhary; Nelesh P Govender; Arnaldo Lopes Colombo; Belinda Calvo; Christina A Cuomo; Christopher A Desjardins; Elizabeth L Berkow; Mariana Castanheira; Rindidzani E Magobo; Kauser Jabeen; Rana J Asghar; Jacques F Meis; Brendan Jackson; Tom Chiller; Anastasia P Litvintseva
Journal:  Clin Infect Dis       Date:  2016-10-20       Impact factor: 9.079

4.  Molecular mechanisms of fluconazole resistance in Candida parapsilosis isolates from a U.S. surveillance system.

Authors:  Nina T Grossman; Cau D Pham; Angela A Cleveland; Shawn R Lockhart
Journal:  Antimicrob Agents Chemother       Date:  2014-12-01       Impact factor: 5.191

5.  Survival, Persistence, and Isolation of the Emerging Multidrug-Resistant Pathogenic Yeast Candida auris on a Plastic Health Care Surface.

Authors:  Rory M Welsh; Meghan L Bentz; Alicia Shams; Hollis Houston; Amanda Lyons; Laura J Rose; Anastasia P Litvintseva
Journal:  J Clin Microbiol       Date:  2017-07-26       Impact factor: 5.948

6.  Epidemiology and Molecular Basis of Resistance to Fluconazole Among Clinical Candida parapsilosis Isolates in Kuwait.

Authors:  Mohammad Asadzadeh; Suhail Ahmad; Noura Al-Sweih; Ziauddin Khan
Journal:  Microb Drug Resist       Date:  2017-03-29       Impact factor: 3.431

7.  Multidrug Transporters and Alterations in Sterol Biosynthesis Contribute to Azole Antifungal Resistance in Candida parapsilosis.

Authors:  Elizabeth L Berkow; Kayihura Manigaba; Josie E Parker; Katherine S Barker; Stephen L Kelly; P David Rogers
Journal:  Antimicrob Agents Chemother       Date:  2015-07-13       Impact factor: 5.191

8.  Candida parapsilosis Resistance to Fluconazole: Molecular Mechanisms and In Vivo Impact in Infected Galleria mellonella Larvae.

Authors:  Ana Carolina R Souza; Beth Burgwyn Fuchs; Henrique M S Pinhati; Ricardo A Siqueira; Ferry Hagen; Jacques F Meis; Eleftherios Mylonakis; Arnaldo L Colombo
Journal:  Antimicrob Agents Chemother       Date:  2015-08-10       Impact factor: 5.191

  8 in total
  23 in total

1.  Evaluation of Two Commercial Broth Microdilution Methods Using Different Interpretive Criteria for the Detection of Molecular Mechanisms of Acquired Azole and Echinocandin Resistance in Four Common Candida Species.

Authors:  Ha Jin Lim; Jong Hee Shin; Mi-Na Kim; Dongeun Yong; Seung A Byun; Min Ji Choi; Seung Yeob Lee; Eun Jeong Won; Seung-Jung Kee; Soo Hyun Kim; Myung-Geun Shin
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

2.  General hospital outbreak of invasive candidiasis due to azole-resistant Candida parapsilosis associated with an Erg11 Y132F mutation.

Authors:  Dora E Corzo-Leon; Mark Peacock; Patricia Rodriguez-Zulueta; Grace J Salazar-Tamayo; Donna M MacCallum
Journal:  Med Mycol       Date:  2021-07-06       Impact factor: 4.076

3.  Hospital outbreak of fluconazole-resistant Candida parapsilosis: arguments for clonal transmission and long-term persistence.

Authors:  Arnaud Fekkar; Marion Blaize; Adrien Bouglé; Anne-Cécile Normand; Audrey Raoelina; Dimitri Kornblum; Laure Kamus; Renaud Piarroux; Sébastien Imbert
Journal:  Antimicrob Agents Chemother       Date:  2021-02-16       Impact factor: 5.191

4.  Evidence of Fluconazole-Resistant Candida parapsilosis Genotypes Spreading across Hospitals Located in Madrid, Spain and Harboring the Y132F ERG11p Substitution.

Authors:  Pilar Escribano; Jesús Guinea; Judith Díaz-García; Ana Gómez; Luis Alcalá; Elena Reigadas; Carlos Sánchez-Carrillo; Ana Pérez-Ayala; Elia Gómez-García de la Pedrosa; Fernando González-Romo; Paloma Merino-Amador; María Soledad Cuétara; Coral García-Esteban; Inmaculada Quiles-Melero; Nelly Daniela Zurita; María Muñoz-Algarra; Isabel Sánchez-Romero; María Teresa Durán-Valle; Aída Sánchez-García; Eva Alcoceba; Patricia Muñoz
Journal:  Antimicrob Agents Chemother       Date:  2022-07-19       Impact factor: 5.938

5.  Candida parapsilosis Mdr1B and Cdr1B Are Drivers of Mrr1-Mediated Clinical Fluconazole Resistance.

Authors:  Laura A Doorley; Jeffrey M Rybak; Elizabeth L Berkow; Qing Zhang; Joachim Morschhäuser; P David Rogers
Journal:  Antimicrob Agents Chemother       Date:  2022-06-14       Impact factor: 5.938

6.  First Report of Candidemia Clonal Outbreak Caused by Emerging Fluconazole-Resistant Candida parapsilosis Isolates Harboring Y132F and/or Y132F+K143R in Turkey.

Authors:  Amir Arastehfar; Farnaz Daneshnia; Suleyha Hilmioğlu-Polat; Wenjie Fang; Melike Yaşar; Furkan Polat; Dilek Yeşim Metin; Petra Rigole; Tom Coenye; Macit Ilkit; Weihua Pan; Wanqing Liao; Ferry Hagen; Markus Kostrzewa; David S Perlin; Cornelia Lass-Flörl; Teun Boekhout
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

7.  Prevalence and Clonal Distribution of Azole-Resistant Candida parapsilosis Isolates Causing Bloodstream Infections in a Large Italian Hospital.

Authors:  Cecilia Martini; Riccardo Torelli; Theun de Groot; Elena De Carolis; Grazia Angela Morandotti; Giulia De Angelis; Brunella Posteraro; Jacques F Meis; Maurizio Sanguinetti
Journal:  Front Cell Infect Microbiol       Date:  2020-05-25       Impact factor: 5.293

Review 8.  The Fungal CYP51s: Their Functions, Structures, Related Drug Resistance, and Inhibitors.

Authors:  Jingxiang Zhang; Liping Li; Quanzhen Lv; Lan Yan; Yan Wang; Yuanying Jiang
Journal:  Front Microbiol       Date:  2019-04-24       Impact factor: 5.640

9.  Molecular Identification, Genotypic Diversity, Antifungal Susceptibility, and Clinical Outcomes of Infections Caused by Clinically Underrated Yeasts, Candida orthopsilosis, and Candida metapsilosis: An Iranian Multicenter Study (2014-2019).

Authors:  Amir Arastehfar; Sadegh Khodavaisy; Farnaz Daneshnia; Mohammad-Javad Najafzadeh; Shahram Mahmoudi; Arezoo Charsizadeh; Mohammad-Reza Salehi; Hossein Zarrinfar; Abbas Raeisabadi; Somayeh Dolatabadi; Zahra Zare Shahrabadi; Kamiar Zomorodian; Weihua Pan; Ferry Hagen; Teun Boekhout
Journal:  Front Cell Infect Microbiol       Date:  2019-07-30       Impact factor: 5.293

10.  Disk Diffusion Susceptibility Testing for the Rapid Detection of Fluconazole Resistance in Candida Isolates.

Authors:  Suhak Jeon; Jong Hee Shin; Ha Jin Lim; Min Ji Choi; Seung A Byun; Dain Lee; Seung Yeob Lee; Eun Jeong Won; Soo Hyun Kim; Myung Geun Shin
Journal:  Ann Lab Med       Date:  2021-11-01       Impact factor: 3.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.